[Hodgkin's Lymphoma].
With approximately 1500 cases per year in France, Hodgkin's lymphoma (HL) represents only 10 to 15 % of new cases of lymphomas, and 0.5 to 1 % of new cases of cancers. The management of this lymphoproliferative disease has undergone profound conceptual changes over time, allowing at present to obtain a cure rate of 75 to 80 % of all confused stage, and up to 90 % in case of early stage HL. If initial treatment consisted in an exclusive extensive (total or sub-total lymphoid) irradiation whatever the stage may be, the place of radiotherapy in the management of HL has evolved over time but remains today one of the cornerstones of the treatment. It becomes integrated within the framework of combined modality therapies associating chemotherapy then irradiation for the early stage HL, and stays a therapeutic alternative in all situations (in advanced stage and\or recurrent disease) which raises the issue of increasing the locoregional tumor control. Despite the undeniable contribution of radiotherapy in controlling the disease, delayed side effects of treatments are not negligible. So the long-term monitoring of treated patients is essential, mainly because of an increased risk of morbi-mortality due to cardiovascular events and/or secondary cancers. It is important to remember that even today the "Involved Field" irradiation type remains the gold standard, even if we witness at present the emergence of new types of irradiation, which aim to reduce the amount of irradiated tissues to try to limit the risks of delayed radio-induced complications. The purpose of this article is to clarify the specific aspects (epidemiological, radio-anatomical and prognostic characteristics) of HL, as well as the practical modalities of the irradiation (illustrated by a clinical case record) when an indication of radiotherapy is placed for its treatment.
Service de radiothérapie du Centre René-Gauducheau, CRLCC Nantes-Atlantiques, Boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France.
F
F
Drouet
X
X
Cahu
Y
Y
Pointreau
F
F
Denis
M A
MA
Mahé
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D005602:France / Q000453:epidemiology; D006689:Hodgkin Disease / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D015994:Incidence; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents